What's hot
View all perspectives
What's Hot
Rheumatoid Arthritis Comorbidities
Dr. Jonathan Kay reviews rheumatoid arthritis studies presented on day at EULAR 2022. Specifically, he discusses abstracts OP0132, OP0135 and OP0138.
Watch video →
Increasing Secukinumab Dose in Ankylosing Spondylitis Nonresponders
Dr. Peter Nash discusses abstract OP0023 from EULAR 2022.
Watch video →
DMARDS, Prednisone, Pregnancy, OH MY!
Dr. Kathryn Dao discusses abstracts POS1405, POS0696 and OP0130 presented at the EULAR 2022 meeting. Watch more videos from EULAR 2022 here: https://rheumnow.com/videos.
Watch video →
Breathing New Insight into RA Interstitial Lung Disease
Dr. Jonathan Kay reviews EULAR 2022 abstracts OP0132, OP0306, and OP0307.
Watch video →
EULAR 2022 - Day 4 Faculty Panel Recap
Dr. David Liew and Dr. Jack Cush discuss day 4 of EULAR 2022. LB0001, LB0002, LB0004, and LB0006.
Watch video →
Getting to the Heart of JAK Inhibitors
Dr. Jonathan Kay reviews rheumatoid arthritis sessions and abstracts from day 3 at EULAR 2022. Abstracts reviewed: OP0266; OP0258; and OP0269.
Watch video →
EULAR 2022 - Day 3 Faculty Panel Recap
Drs. Jack Cush, Janet Pope, Aurelie Najm and Yuz Yusof discuss highlights from Day 3 of EULAR 2022.
Watch video →
Deucravacitinib at EULAR 2022
Dr. Peter Nash provides and update on the TYK2 inhibitor, Deucravacitinib with reports on: - Safety of Deucravacitinib https://bit.ly/3NtZQxe - Deucravacitinib in SLE https://bit.ly/3Mh5nG0
Watch video →
Richard Conway RichardPAConway
3 years 6 months ago
Burja et al. Dimethyl alpha-ketoglutarate has anti-inflammatory and anti-fibrotic effects on explanted systemic sclerosis skin. @RheumNow #EULAR2022 OP0095 https://t.co/PSbnVh6uta https://t.co/2ij9HgoU6Q
Dr. John Cush RheumNow
3 years 6 months ago
RheumNow Coverage of #EULAR2022 Presents Live Expert Discussions https://t.co/FeE0WfXw1z
Richard Conway RichardPAConway
3 years 6 months ago
Phase 3 RCT upadacitinib in nrAxSpA. Clinical (ASAS40), PRO, and radiologic response seen at week 14 vs placebo @RheumNow #EULAR2022 OP0016 https://t.co/s3Vf4QiiAD https://t.co/gzlxZ3sxHF
Eric Dein ericdeinmd
3 years 6 months ago
#EULAR2022 OP0073: Gender-specific assessment for MRI imaging criteria
⭐️Sex differences in axSpA - disease presentations, jt biomechanics, diagnostic delay in ♀️
⭐️Higher fat metaplasia in ♂️, Sclerosis in ♀️
⭐️Ankylosis much higher in ♂️ (DOR 40!)
@Rheumnow
Janet Pope Janetbirdope
3 years 6 months ago
#What’sHot? Axial PsA cohort as some drugs seem to work differently in axPsA vs axSpA Less HLAB27+, less male, 17% isolated axial in PsA #OP0026 @RheumNow #EULAR2022 @eular_org https://t.co/I0azSymVrr
Richard Conway RichardPAConway
3 years 6 months ago
Intra-articular morphine in knee arthritis. WHAT!? Not-surprisingly it doesn't work. Inferior to steroid and same as placebo. Still kudos to Haibel et al for answering this question @RheumNow #EULAR2022 OP0050 https://t.co/zjY36V9OCS https://t.co/j67omCQCxI
Md Yuzaiful Md Yusof Yuz6Yusof
3 years 6 months ago
#POS0086PARE #EULAR2022 What #lupus symptoms/target mattered most to the patients?A survey in 342 found reduction in joint pain, rash & non-joint pain as most important. Reduced infection risk was the least. Important to be aware in assessing patients & guide studies @RheumNow https://t.co/pGXxklj1mt
David Liew drdavidliew
3 years 6 months ago
Minimal disease activity achivement by PsA domain over 2y, in guselkumab phase 3
Everyone goes on about skin efficacy with guselkumab, but pretty good early on for enthesitis & swollen joints too... has challenged my uninformed thinking!
POS1067 #EULAR2022 #IL23 @RheumNow https://t.co/chCWeFd05o
Aurelie Najm AurelieRheumo
3 years 6 months ago
↘️Education level🟰↗️risk of clinical RA in at risk patients. HR=1.8 although partially explained by ↗️ MRI inflammation at Dx.
Adjusted on smoking status, age and BMI.
Shall we follow this group of patients more closely?
OP0035 #EULAR2022 @RheumNow https://t.co/8EJZpaxn3k
Aurelie Najm AurelieRheumo
3 years 6 months ago
🔜 Remission in PsA : the earlier the better ⏰
Dutch cohort (DEPAR) 300+pts
Failure to achieve MDA 1yr post diagnosis
🧨worst QoL yr 1️⃣2️⃣&3️⃣
🧨↗️bioDMARDs use over time
🧨no recovery
#OP0028 #EULAR2022 @RheumNow https://t.co/IS6ySIQvBP
David Liew drdavidliew
3 years 6 months ago
PMR bursas are filled with macrophage subtypes esp CD68+, expressing IL-6 & GM-CSF.
PMR is now far from just a vibe - real science, real targets for therapy.
Not every day that PMR basic science makes it on stage, lovely from @VasculitisUMCG @jiemy_william
#EULAR2022 @RheumNow https://t.co/zem3JEosQL
Richard Conway RichardPAConway
3 years 6 months ago
Jiemy et al. Phenotyping monocytes/macrophages in PMR. Synovial/bursal macrophages have pro-inflammatory phenotype with prominent IL-6 and GM-CSF response. Rationale for tocilizumab/mavrilimumab @RheumNow #EULAR2022 OP0015 https://t.co/53GJkL4BcP
Aurelie Najm AurelieRheumo
3 years 6 months ago
Retrospective nation-wide italian study:
Long term exposure to :
🌫 PM10 ⬆️ risk of RA aOR 1.4 but not other AI diseases
🚗PM2.5 ⬆️ risk of RA aOR 1.6 CTDs aOR 1.1 IBDs aOR 1.2
OP0071 #EULAR2022 @Rheumnow https://t.co/HOOEnh7KWW
TheDaoIndex KDAO2011
3 years 6 months ago
Pre-clinical RA TREAT EARLIER Trial: #Plenary OP0070
RDBPCT eval temporary MTX vs PCB in 136 pts with arthralgias >2 weeks at risk for RA (MRI hand/forefoot w/subclinical inflammation) followed for 2 yrs; 1/3 +ACPA. Rx 1 yr can delay but won’t prevent RA. #EULAR2022 @rheumnow https://t.co/v1GWOBFstz
Dr. John Cush RheumNow
3 years 6 months ago
EULAR 2022 Featured Industry Abstracts
Review is a collection of several EULAR 2022 abstracts highlighted in recent press releases from companies sponsoring major clinical trials. You can search the EULAR site for these abstract and others here.
https://t.co/ggnAyuvAbl https://t.co/WjKDb70RkW
Poster Hall